MSLN and cancer: Our data suggest that lowered mesothelin expression level correlates with anti-cancer efficacy observed in animal studies, thus strengthening the rationale for combinatory treatment using oncolytic adenovirus AdV5/3-D24-ICOSL-CD40L with anti-PD-1 in mesothelioma therapy.